In conclusion, our RT- and ChIP-qPCR analysis confirmed the observed p53-mediated response in HME-treated HepG2 cells and linked it with increased recruitment of p53 and p300 at the chromatin of the upregulated loci, as part of an overall anti-cancer response that was observed in this cell line, in contrast to the Ls174 cells in which HME treatment was mostly associated with metabolic effects (Fig. 6). This evidence concerns the gene TP53 and cancer.